Fig. 1
From: Cardiotoxicity risk factors with immune checkpoint inhibitors
Percentage of adverse cardiac event (atrial fibrillation with rapid ventricular response, heart failure with preserved/reduced ejection fraction, myocarditis, pericarditis, ventricular fibrillation/tachycardia) out of respective study population treated with immune checkpoint inhibitors. Total population for each category: African American (AA) Male 35, AA Female 22, Caucasian (Cau) Male 299, Cau Female 169. Fisher’s Exact P = 0.057 between AA and Cau male and P = 0.176 between AA and Cau females